probably indicates a more accelerated intimal hyperplasia, greater degree of vascular inflammation and/or endothelial dysfunction, and increased plaque vulnerability in insulin-treated diabetic patients, and highlights the need for
An analysis of patients with insulin-treated diabetes found that 38% of those with late-onset type 1 diabetes did not receive insulin at diagnosis, nearly half of whom reported a type 2 diabetes diagnosis.
A recent scientific statement on diabetes and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes on outcomes in heart failure; reviews pharmacological therapy and lifestyle modification; highlights the value
Other independent predictors of long-term weight loss included greater weight loss in the first year and older age, according to this follow-up analysis of the Diabetes Prevention Program.
Patients with type 1 diabetes and a mean three-year HbA1c level greater than 8.0% had a higher fracture risk than those with a mean three-year HbA1c level of 7.0% or less.
Real-time continuous glucose monitoring (CGM), with either an insulin pump or multiple daily injections, was associated with sustained improvements in HbA1c levels compared to self-monitoring of blood glucose, according to a small randomized trial.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke
Patients' perceived helpfulness of certain actions by health care professionals was linked to earlier insulin initiation and greater insulin continuation over time, a survey found.
Patients with diabetes and obesity who had metabolic surgery were matched in a 1:5 ratio to those who received usual care, with incidence of a major cardiovascular event (MACE) as the primary outcome.
The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.